NuCana (NASDAQ:NCNA) has been given an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus target price of $26.50 for the company and are anticipating that the company will post ($0.22) earnings per share for the current quarter, according to Zacks. Zacks has also given NuCana an industry rank of 183 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut NuCana from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th.
Several large investors have recently modified their holdings of the company. Sofinnova Management VIII L.L.C. boosted its stake in shares of NuCana by 600.0% in the fourth quarter. Sofinnova Management VIII L.L.C. now owns 4,666,666 shares of the company’s stock valued at $47,180,000 after buying an additional 4,000,000 shares during the period. Alliancebernstein L.P. boosted its stake in shares of NuCana by 40.1% in the fourth quarter. Alliancebernstein L.P. now owns 910,358 shares of the company’s stock valued at $9,204,000 after buying an additional 260,358 shares during the period. UBS Asset Management Americas Inc. boosted its stake in shares of NuCana by 4.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 464,600 shares of the company’s stock valued at $4,697,000 after buying an additional 19,800 shares during the period. Alps Advisors Inc. bought a new stake in shares of NuCana in the fourth quarter valued at approximately $357,000. Finally, Perceptive Advisors LLC bought a new stake in shares of NuCana in the third quarter valued at approximately $3,674,000. Institutional investors own 30.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3341408/nucana-ncna-given-average-rating-of-strong-buy-by-analysts.html.
NuCana plc, a biopharmaceutical company, engages in the development of products for the treatment of cancer. The company is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; that is in Phase Ib clinical trials for the treatment of recurrent ovarian cancer; in Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.